<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PILOCARPINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PILOCARPINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Primary angle-closure glaucoma</span>,
                <span class="indication">Some secondary glaucomas</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply up to 4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Xerostomia following irradiation for head and neck cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg 3 times a day for 4 weeks, then increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with or immediately after meals (last dose always with evening meal), maximum therapeutic effect normally within 4&#8211;8 weeks; discontinue if no improvement after 2&#8211;3 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dry mouth and dry eyes in Sj&#246;gren&#8217;s syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg 4 times a day; increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with meals and at bedtime, discontinue if no improvement after 2&#8211;3 months.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Pilocarpine acts by opening the inefficient drainage channels in the trabecular meshwork.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Avoid unless the potential benefit outweighs risk&#8212;limited information available.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid&#8212;smooth muscle stimulant; toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Reduce initial oral dose in moderate or severe cirrhosis.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Manufacturer advises caution with tablets.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> influenza-like symptoms, abdominal pain, asthenia, conjunctivitis, constipation, diarrhoea, dizziness, dyspepsia, flushing, headache, hypertension, increased urinary frequency, lacrimation, nausea, ocular pain, palpitation, pruritus, rash, rhinitis, sweating, visual disturbances, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> flatulence, urinary urgency,
              </p>
              <p>
                <strong>rare:</strong> parasympathomimetics systemic side effects,
              </p>
              <p>
                <strong>notKnown:</strong> blurred vision, ciliary spasm (leads to headache and browache which may be more severe in the initial 2&#8211;4 weeks of treatment&#8212;a particular disadvantage in patients under 40 years of age), conjunctival vascular congestion, lens changes (with chronic use), myopia, ocular burning, ocular itching, pupillary block, smarting, vitreous haemorrhage,
              </p>
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by eye:</strong>
            a darkly pigmented iris may require a higher concentration of the miotic or more frequent administration and care should be taken to avoid overdosage
          </li>
          <li>
              <strong>When used by eye:</strong>
            asthma
          </li>
          <li>
              <strong>When used by eye:</strong>
            cardiac disease
          </li>
          <li>
              <strong>When used by eye:</strong>
            care in conjunctival damage
          </li>
          <li>
              <strong>When used by eye:</strong>
            care in corneal damage
          </li>
          <li>
              <strong>When used by eye:</strong>
            epilepsy
          </li>
          <li>
              <strong>When used by eye:</strong>
            gastro-intestinal spasm
          </li>
          <li>
              <strong>When used by eye:</strong>
            hypertension
          </li>
          <li>
              <strong>When used by eye:</strong>
            hyperthyroidism
          </li>
          <li>
              <strong>When used by eye:</strong>
            hypotension
          </li>
          <li>
              <strong>When used by eye:</strong>
            marked vasomotor instability
          </li>
          <li>
              <strong>When used by eye:</strong>
            Parkinson&#8217;s disease
          </li>
          <li>
              <strong>When used by eye:</strong>
            peptic ulceration
          </li>
          <li>
              <strong>When used by eye:</strong>
            retinal detachment has occurred in susceptible individuals and those with retinal disease
          </li>
          <li>
              <strong>When used by eye:</strong>
            urinary-tract obstruction
          </li>
          <li>
              <strong>With oral use:</strong>
            asthma (avoid if uncontrolled)
          </li>
          <li>
              <strong>With oral use:</strong>
            biliary-tract disease
          </li>
          <li>
              <strong>With oral use:</strong>
            cardiovascular disease (avoid if uncontrolled)
          </li>
          <li>
              <strong>With oral use:</strong>
            cholelithiasis
          </li>
          <li>
              <strong>With oral use:</strong>
            chronic obstructive pulmonary disease (avoid if uncontrolled)
          </li>
          <li>
              <strong>With oral use:</strong>
            cognitive disturbances
          </li>
          <li>
              <strong>With oral use:</strong>
            maintain adequate fluid intake to avoid dehydration associated with excessive sweating
          </li>
          <li>
              <strong>With oral use:</strong>
            peptic ulceration
          </li>
          <li>
              <strong>With oral use:</strong>
            psychiatric disturbances
          </li>
          <li>
              <strong>With oral use:</strong>
            risk of increased renal colic
          </li>
          <li>
              <strong>With oral use:</strong>
            risk of increased urethral smooth muscle tone
          </li>
          <li>
              <strong>With oral use:</strong>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Intra-ocular pressure and visual fields should be monitored in those with chronic simple glaucoma and those receiving long-term treatment with a miotic.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Although multi-dose pilocarpine eye drops commonly contain preservatives preservative-free unit dose vials may be available.</p>
            </section>
      </section>




      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Fundus examination is advised before starting treatment with a miotic (retinal detachment has occurred).</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PILOCARPINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            eye drops,

            <div id="PHP77738"><a href="../medicinalForm/PHP77738.html" data-target="#PHP77738" data-action="load">Tablet</a></div>
            <div id="PHP77747"><a href="../medicinalForm/PHP77747.html" data-target="#PHP77747" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
